[go: up one dir, main page]

BG104839A - Chrystalline form of paroxetine - Google Patents

Chrystalline form of paroxetine

Info

Publication number
BG104839A
BG104839A BG104839A BG10483900A BG104839A BG 104839 A BG104839 A BG 104839A BG 104839 A BG104839 A BG 104839A BG 10483900 A BG10483900 A BG 10483900A BG 104839 A BG104839 A BG 104839A
Authority
BG
Bulgaria
Prior art keywords
paroxetine
chrystalline
free
therapy
pure
Prior art date
Application number
BG104839A
Other languages
Bulgarian (bg)
English (en)
Inventor
Andrew Craig
Neal Ward
WAINE Wilson McIL
Original Assignee
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9805581.7A external-priority patent/GB9805581D0/en
Priority claimed from GBGB9813054.5A external-priority patent/GB9813054D0/en
Priority claimed from GBGB9817115.0A external-priority patent/GB9817115D0/en
Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc
Publication of BG104839A publication Critical patent/BG104839A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
BG104839A 1998-03-16 2000-10-11 Chrystalline form of paroxetine BG104839A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB9805581.7A GB9805581D0 (en) 1998-03-16 1998-03-16 Novel compounds
GBGB9813054.5A GB9813054D0 (en) 1998-06-17 1998-06-17 Novel compounds
GBGB9817115.0A GB9817115D0 (en) 1998-08-06 1998-08-06 Novel compounds
PCT/GB1999/000793 WO1999047519A1 (en) 1998-03-16 1999-03-16 Crystalline form of paroxetine

Publications (1)

Publication Number Publication Date
BG104839A true BG104839A (en) 2001-09-28

Family

ID=27269245

Family Applications (1)

Application Number Title Priority Date Filing Date
BG104839A BG104839A (en) 1998-03-16 2000-10-11 Chrystalline form of paroxetine

Country Status (18)

Country Link
EP (1) EP1064282A1 (xx)
JP (1) JP2002506865A (xx)
KR (1) KR20010041947A (xx)
CN (1) CN1300286A (xx)
AP (1) AP2000001907A0 (xx)
AU (1) AU2847199A (xx)
BG (1) BG104839A (xx)
BR (1) BR9908825A (xx)
CA (1) CA2323896A1 (xx)
EA (1) EA200000946A1 (xx)
HU (1) HUP0101215A3 (xx)
ID (1) ID27596A (xx)
IL (1) IL138390A0 (xx)
NO (1) NO20004583L (xx)
PL (1) PL342931A1 (xx)
SK (1) SK13622000A3 (xx)
TR (1) TR200002675T2 (xx)
WO (1) WO1999047519A1 (xx)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH689805A8 (fr) * 1998-07-02 2000-02-29 Smithkline Beecham Plc Méthanesulfonate de paroxétine, procédé pour sa préparation et compositions pharmaceutiques le contenant.
GB9919052D0 (en) * 1999-08-12 1999-10-13 Smithkline Beecham Plc Novel compound composition and process
US20080033050A1 (en) 2006-08-04 2008-02-07 Richards Patricia Allison Tewe Method of treating thermoregulatory disfunction with paroxetine

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1422263A (en) * 1973-01-30 1976-01-21 Ferrosan As 4-phenyl-piperidine compounds
ES2058061T3 (es) * 1985-10-25 1994-11-01 Beecham Group Plc Derivado de piperidina, su preparacion y su uso como medicamento.
AR001982A1 (es) * 1995-02-06 1998-01-07 Smithkline Beecham Plc Clorhidrato de paroxetina anhidratado, y procedimiento para su preparacion

Also Published As

Publication number Publication date
EP1064282A1 (en) 2001-01-03
HUP0101215A2 (hu) 2002-04-29
KR20010041947A (ko) 2001-05-25
TR200002675T2 (tr) 2000-12-21
EA200000946A1 (ru) 2001-02-26
NO20004583D0 (no) 2000-09-14
BR9908825A (pt) 2000-11-21
ID27596A (id) 2001-04-12
CA2323896A1 (en) 1999-09-23
CN1300286A (zh) 2001-06-20
PL342931A1 (en) 2001-07-16
AU2847199A (en) 1999-10-11
NO20004583L (no) 2000-09-15
IL138390A0 (en) 2001-10-31
AP2000001907A0 (en) 2000-09-30
JP2002506865A (ja) 2002-03-05
HUP0101215A3 (en) 2002-05-28
WO1999047519A1 (en) 1999-09-23
SK13622000A3 (sk) 2001-03-12

Similar Documents

Publication Publication Date Title
MY135732A (en) 5,6-trimethylenepyrimidin - 4 - one compounds
MY114014A (en) Imidazole compounds, compositions and use
PL327735A1 (en) Novel substituted derivatives of imidazole
HU9503605D0 (en) Use of nona- and decapeptides in the preparation of a drug for the treatment of aids
PL327934A1 (en) Novel substituted imidazole compounds
CY2473B1 (en) New phenanthridines.
PL349028A1 (en) Cancer treatment composition and method using natural plant essential oils
MY119403A (en) Novel compounds with analgesic effect.
ZA975443B (en) Use of pyridyl alkane, pyridyl alkene and/or pyridyl alkine acid amides.
HK1029922A1 (en) Angiostatic agents and compositions for treating glc1a glaucoma
AU5186799A (en) Peptides of il-2 and derivatives thereof and their use as therapeutic agents
HU229458B1 (en) Pharmaceutical compositions containing zolmitriptan
YU13301A (sh) Muskarinski agonisti i antagonisti
PL340561A1 (en) Application of a combination of a converting enzyme inhibitor and a diuretic in treating microcirculatory disorders
PL316656A1 (en) Free halophantrin base for use in treating marsh-fever and compositions containing same
IL126235A (en) Compounds with growth hormone releasing properties, pharmaceutical compositions comprising them and their use
MY120550A (en) Substituted 1,2,3,4,5,6-hexahydro-2,6-methano-3-benzazocin-10-ols, processes for preparing them and their use as pharmaceutical compositions.
AU2982495A (en) Heterocycle-condensed morphinoid derivatives
MX9707875A (es) Levobupivacaina y su uso como un anestesico en mujeres embarazadas.
BG100248A (en) Squalene synthetase inhibitors
NZ335052A (en) Piperazino derivatives as neurokinin antagonists
IL106237A0 (en) Piperidyl amides,sulfonamides and sulfoxamides as inhibitors of cholesterol biosynthesis
BG104839A (en) Chrystalline form of paroxetine
NZ515531A (en) Substituted 3-pyridyl-4-arylpyrroles, and related therapeutic and prophylactic methods
GEP20043313B (en) Use of Pharmaceutical Composition for Treatment of Endometriosis or Infertility, or Improving Fertility